Want to see SOPH full AI Analyst Report?
Top Page
SOPHiA GENETICS
(NASDAQ:SOPH)
Select Model
Select Model
Rating:54Neutral
Price Target:
$6.00
▲(13.64% Upside)
Action:Reiterated
Date:05/09/26
The score is constrained primarily by weak financial performance—large ongoing losses, material cash burn, and increased leverage—despite strong gross margins and improving revenue scale. Offsetting this, the latest earnings call indicates improving operating trajectory (reaffirmed growth outlook and better adjusted EBITDA guidance) and technical signals are modestly supportive with price trading above key moving averages.
Positive Factors
High adjusted gross margins
Sustained adjusted gross margins near 75% indicate strong unit economics for SOPHiA's analytics platform. High margins provide durable operating leverage as volume scales, enabling the company to invest in product development and sales while improving the path to adjusted EBITDA break-even as revenue grows.
Negative Factors
Persistent cash burn
Substantial negative operating and free cash flow reduces financial flexibility and makes the business dependent on external funding or credit. Even with improvement versus prior years, ongoing cash consumption could force dilution, constrain strategic investments, or require tighter cost controls before sustained profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
High adjusted gross margins
Sustained adjusted gross margins near 75% indicate strong unit economics for SOPHiA's analytics platform. High margins provide durable operating leverage as volume scales, enabling the company to invest in product development and sales while improving the path to adjusted EBITDA break-even as revenue grows.
Read all positive factors
SOPHiA GENETICS Key Performance Indicators (KPIs)
Any
Revenue by Segment
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Data provided by:
The Fly
The FlySOPHiA GENETICS (SOPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$462.26M
Dividend YieldN/A
Average Volume (3M)100.95K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth20.85%
EPS Growth-18.60%
CountryUS
Employees423
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.18
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue4.59
Enterprise Value/Gross Profit6.82
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$7.50Price Target Upside42.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$93.40M
SOPHiA GENETICS Business Overview & Revenue Model
Company Description
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and v...
How the Company Makes Money
SOPHiA GENETICS generates revenue primarily by providing access to its cloud-based analytics platform and related software services used to process and interpret customer medical data. Its revenue model typically includes (1) recurring or subscrip...
SOPHiA GENETICS Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call portrayed a broadly constructive operational and commercial story: strong top-line growth (22% YoY), record analysis volumes, healthy unit economics (high adjusted gross margin ~75%), improved net dollar retention (117%), and accelerating application and biopharma momentum. Management also took targeted cost actions, expanded liquidity and reaffirmed full-year guidance. Offsetting these positives were higher cash burn, an increased operating loss, FX translation headwinds (Swiss franc up ~14% vs USD), ongoing litigation costs, and softness in Latin America. Growth is expected to be back-half weighted, which introduces execution risk for the year. Overall, the company shows strengthening fundamentals and a clear path toward profitability, but faces near-term cost, FX and legal headwinds that require monitoring.Positive Updates
Strong Revenue Growth
Total revenue of $21.7M in Q1 2026, up 22% year-over-year from $17.8M in Q1 2025; company reaffirmed full-year 2026 revenue guidance of $92M–$94M (20%–22% growth).
Negative Updates
Operating Loss and Elevated Operating Expenses
Operating loss widened to $17.3M in Q1 2026 (vs $16.0M prior year); total operating expenses increased to $32.0M from $28.2M YoY, driven in part by FX translation effects and litigation costs.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue of $21.7M in Q1 2026, up 22% year-over-year from $17.8M in Q1 2025; company reaffirmed full-year 2026 revenue guidance of $92M–$94M (20%–22% growth).
Read all positive updates
Company Guidance
SOPHiA reaffirmed full‑year 2026 revenue guidance of $92–94 million (growth of 20–22% on a reported basis) and adjusted EBITDA loss guidance of $29–32 million (improved from $41.5M in 2025), noting revenue will be mostly back‑half weighted and that they expect modest gross‑margin expansion and to be approaching adjusted‑EBITDA breakeven by end‑2026 with positive adjusted EBITDA in H2 2027. Management anchored the outlook in Q1 results — revenue $21.7M (+22% YoY), ~108,000 analyses (+16% YoY; March record >40,000/month), adjusted gross margin 75.4%, adjusted gross profit $16.4M and an adjusted EBITDA loss of $9.2M — and in strong commercial metrics (537 core genomic customers vs. 490 a year ago, net dollar retention 117%, annualized churn <1%). They expect ASP lift (clinical ASP ≈ $195 in Q1; sequential +$2; mix range $100–$500) as higher‑value tests and pharma work ramp in H2, while reiterating cost discipline, calling out Q1 cash burn of $19.5M, cash on hand of $65.4M (including $14.5M ATM proceeds), a $25M credit facility expansion, and potential reported‑results impacts from FX volatility (Swiss franc ~+14% vs. USD) and ongoing litigation (Q1 legal spend ~$1.4M; net impact ≈$700K after recoveries).SOPHiA GENETICS Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 81.18M | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M |
| Gross Profit | 54.62M | 47.81M | 43.94M | 42.91M | 31.25M | 25.22M |
| EBITDA | -66.08M | -64.40M | -50.76M | -69.57M | -81.38M | -69.24M |
| Net Income | -80.94M | -79.00M | -62.49M | -78.98M | -87.45M | -73.67M |
Balance Sheet | ||||||
| Total Assets | 157.00M | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M |
| Cash, Cash Equivalents and Short-Term Investments | 65.39M | 70.29M | 80.23M | 123.25M | 178.61M | 265.32M |
| Total Debt | 62.42M | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M |
| Total Liabilities | 111.31M | 116.31M | 58.82M | 54.71M | 43.71M | 44.77M |
| Stockholders Equity | 45.69M | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M |
Cash Flow | ||||||
| Free Cash Flow | -45.43M | -38.59M | -51.00M | -57.80M | -80.47M | -64.61M |
| Operating Cash Flow | -42.12M | -38.01M | -42.82M | -48.58M | -70.09M | -57.94M |
| Investing Cash Flow | -10.93M | -10.51M | -8.18M | 8.32M | 41.97M | -56.93M |
| Financing Cash Flow | 46.34M | 34.13M | 11.59M | -2.82M | -1.57M | 237.77M |
SOPHiA GENETICS Technical Analysis
Positive
5.28
Price Trends
5.14
Positive
4.96
Positive
4.80
Positive
Market Momentum
0.12
Positive
54.48
Neutral
35.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOPH, the sentiment is Positive. The current price of 5.28 is below the 20-day moving average (MA) of 5.39, above the 50-day MA of 5.14, and above the 200-day MA of 4.80, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 54.48 is Neutral, neither overbought nor oversold. The STOCH value of 35.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOPH.
SOPHiA GENETICS Risk Analysis
SOPHiA GENETICS disclosed 1 risk factors in its most recent earnings report. SOPHiA GENETICS reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SOPHiA GENETICS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.37B | ― | -2.81% | ― | 49.36% | 83.76% | |
56 Neutral | $1.20B | -11.91 | -30.85% | ― | 10.59% | 46.79% | |
54 Neutral | $462.26M | -4.93 | -140.63% | ― | 20.85% | -18.60% | |
52 Neutral | $116.71M | -0.49 | -67.07% | ― | -3.89% | 63.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $2.89M | -0.01 | -8.26% | ― | -28.30% | -86.74% | |
51 Neutral | $1.95B | -26.09 | -27.50% | ― | 34.09% | -84.19% |
* Healthcare Sector Average
SOPH
SOPHiA GENETICS
5.82
2.07
55.20%
SDGR
Schrodinger
16.79
-4.92
-22.66%
ZCMD
Zhongchao
2.02
-838.70
-99.76%
WGS
GeneDx Holdings
69.39
-17.52
-20.16%
DH
Definitive Healthcare Corp
0.80
-3.38
-80.86%
OMDA
Omada Health, Inc.
23.55
5.63
31.42%
SOPHiA GENETICS Corporate Events
SOPHiA GENETICS Raises $57.5 Million in June 2026 Share Offering
Jun 22, 2026
On June 16, 2026, SOPHiA GENETICS entered into an underwriting agreement to sell 12,104,900 ordinary shares at $4.75 each, including the full exercise of the underwriters’ option, raising gross proceeds of about $57.5 million. The U.S.-regis...
SOPHiA GENETICS Shareholders Back 2025 Results, Board Line-Up and Capital Changes at June 18 AGM
Jun 22, 2026
On June 18, 2026, SOPHiA GENETICS SA held its annual general meeting, where shareholders overwhelmingly approved the 2025 management report, annual and consolidated financial statements, and the ESG Impact Summary, while discharging the board and ...
SOPHiA GENETICS and MSK Forge Joint Venture MOU to Build Global Precision Oncology Hub
Jun 4, 2026
On June 4, 2026, SOPHiA GENETICS announced it had signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture focused on next-generation precision oncology. The planned precision medicine hub would marr...
SOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact Summary
May 19, 2026
On May 19, 2026, SOPHiA GENETICS SA reported that it has published its Environmental, Social and Governance Impact Summary as of December 31, 2025. The 2025 ESG Impact Summary, made available through the company’s investor relations site, ou...
SOPHiA GENETICS Calls 2026 AGM as It Highlights Breakout 2025 Growth
May 8, 2026
SOPHiA GENETICS SA has invited shareholders to its 2026 annual general meeting, scheduled for June 18, 2026, at the company’s offices in Rolle, Switzerland, with materials such as the formal invitation, meeting notice, and proxy cards distri...
SOPHiA GENETICS Posts Higher Q1 2026 Revenue but Wider Loss in Newly Filed Form 6-K
May 5, 2026
On May 5, 2026, SOPHiA GENETICS SA filed a Form 6-K in the United States, furnishing unaudited interim condensed consolidated financial statements and related management discussion for the three months ended March 31, 2026. The filing, signed by C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.